<style face="normal" font="default" size="100%">Anti-leukemic activity of dasatinib in both p53(wild-type) and p53(mutated) B malignant cells.</style>

Drupal-Biblio

17

<style face="normal" font="default" size="100%">Anti-leukemic activity of dasatinib in both p53(wild-type) and p53(mutated) B malignant cells.</style>

Drupal-Biblio

17

<style face="normal" font="default" size="100%">Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway.</style>

Drupal-Biblio

17

<style face="normal" font="default" size="100%">miR-34a induces the downregulation of both E2F1 and B-Myb oncogenes in leukemic cells.</style>

Drupal-Biblio

17

<style face="normal" font="default" size="100%">Molecular targets for selective killing of TRAIL-resistant leukemic cells.</style>

Drupal-Biblio

17

<style face="normal" font="default" size="100%">Recent advances in the therapeutic perspectives of Nutlin-3.</style>